Tresiba and Finasteride Interaction: Safety, Risks, and Clinical Guidance

Why These Two Drugs Get Prescribed Together

Men with type 2 diabetes who use Tresiba for glycemic control often also develop androgenetic alopecia or benign prostatic hyperplasia, two conditions treated with finasteride. Prescribing overlap is common. The question of whether combining these medications creates a safety concern is reasonable given that both drugs affect hormonal and metabolic pathways, but the pharmacology tells a reassuring story.

Type 2 diabetes affects approximately 37.3 million Americans according to the CDC's 2022 National Diabetes Statistics Report [1]. Androgenetic alopecia affects roughly 50% of men by age 50 [2]. The probability that a single patient needs both basal insulin and a 5-alpha reductase inhibitor is not trivial. Finasteride prescriptions exceeded 20 million annually in the United States by 2020, and insulin degludec (marketed as Tresiba) captured a growing share of the long-acting insulin market following its FDA approval in 2015 [3]. These patient populations overlap frequently in primary care and endocrinology clinics, making the interaction question clinically relevant even though the answer is pharmacologically straightforward.

Pharmacokinetic Analysis: No Meaningful Interaction

Insulin degludec and finasteride occupy entirely separate metabolic pathways, which eliminates the most common mechanism through which two drugs interfere with each other. The FDA-approved prescribing information for Tresiba states that insulin degludec is "degraded in a manner similar to human insulin" and that "no clinically relevant drug-drug interactions have been observed in pharmacokinetic studies" [3]. This degradation happens through nonspecific peptidases in the liver, kidney, and peripheral tissues. It does not involve CYP450 isoenzymes, P-glycoprotein transporters, or other drug-metabolizing systems that most small-molecule medications rely on.

Finasteride, by contrast, is a small-molecule 5-alpha reductase inhibitor metabolized primarily by CYP3A4, with minor contributions from CYP3A5 [4]. It does not inhibit or induce any known CYP450 isoenzyme at therapeutic concentrations. The FDA label for finasteride confirms that "no drug interactions of clinical importance have been identified" in formal interaction studies [4]. Because insulin degludec never enters the CYP system and finasteride neither inhibits nor induces CYP isoenzymes at clinically relevant levels, there is no enzymatic pathway through which one drug could alter the concentration of the other.

Protein binding is another theoretical point of interaction. Finasteride is approximately 90% bound to plasma proteins, primarily albumin [4]. Insulin degludec forms multi-hexamers that bind albumin in the subcutaneous depot and circulation, contributing to its ultra-long half-life of roughly 25 hours [5]. Despite both drugs interacting with albumin, they bind at different sites and at concentrations far too low to create displacement competition. A 1 mg finasteride dose produces peak plasma concentrations in the low nanomolar range, while degludec binds albumin through its fatty acid side chain at a distinct domain. No displacement signal has been reported in clinical practice or formal study.

Pharmacodynamic Considerations: The Androgen-Insulin Sensitivity Link

The more nuanced clinical question is pharmacodynamic. Finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT) by inhibiting type II 5-alpha reductase. This produces a roughly 70% reduction in serum DHT and a modest 10 to 15% increase in total serum testosterone [4]. Androgens influence glucose metabolism, and shifts in the testosterone-to-DHT ratio could theoretically affect insulin sensitivity.

A 2019 meta-analysis published in The Journal of Clinical Endocrinology & Metabolism examining androgen deprivation and metabolic risk found that reductions in androgen signaling were associated with increased fasting glucose and insulin resistance in men, with a pooled odds ratio of 1.36 (95% CI 1.14 to 1.62) for incident diabetes [6]. Finasteride, however, does not reduce total androgen load. It redirects the ratio: less DHT, more testosterone. The net metabolic effect appears small.

A population-based cohort study using data from the U.K. Clinical Practice Research Datalink (CPRD) evaluated over 55,000 men taking finasteride and found no statistically significant increase in new diabetes diagnoses compared with matched controls (HR 1.03 to 95% CI 0.97 to 1.09) [7]. This large dataset provides reassurance that finasteride does not meaningfully worsen glycemic control at the population level.

For patients already on insulin, the concern is more specific: could finasteride shift insulin sensitivity enough to require a dose adjustment? The available evidence says this is unlikely. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that "the relationship between androgens and insulin sensitivity is complex and bidirectional" and that "changes in DHT specifically, independent of total testosterone, have not been consistently associated with clinically meaningful glucose changes in eugonadal men" [8]. Patients on Tresiba who begin finasteride should not expect a clinically significant glycemic shift, but glucose monitoring during the first 4 to 8 weeks remains prudent clinical practice when adding any new medication to an insulin regimen.

Drugs That Actually Interact with Tresiba

While finasteride poses no identified risk, several drug classes do interact with insulin degludec and deserve clinical attention. The Tresiba prescribing information lists categories of drugs that may increase or decrease the blood-glucose-lowering effect of insulin [3].

Drugs that increase hypoglycemia risk when combined with Tresiba:

• Oral antidiabetic agents (sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors)
• ACE inhibitors and angiotensin II receptor blockers
• Monoamine oxidase inhibitors
• Salicylates (high-dose aspirin)
• Fluoxetine and other SSRIs
• Pramlintide

Drugs that may reduce the glucose-lowering effect:

• Corticosteroids (prednisone, dexamethasone)
• Thiazide diuretics
• Thyroid hormones (levothyroxine)
• Sympathomimetic agents (albuterol, pseudoephedrine)
• Atypical antipsychotics (olanzapine, clozapine)
• Protease inhibitors

Beta-blockers and alcohol require special mention because they can either raise or lower blood glucose and may mask hypoglycemic symptoms [3]. Finasteride does not appear in any interaction category for Tresiba, and the pharmacological basis for this absence is well supported by the mechanisms discussed above.

Clinical Monitoring Recommendations

Even with no formal interaction, adding any medication to an insulin regimen warrants a structured monitoring approach. The American Diabetes Association (ADA) Standards of Care recommend that "patients on insulin therapy should increase self-monitoring of blood glucose when starting or stopping concomitant medications that could affect glucose levels" [9]. This recommendation applies regardless of whether a known interaction exists, because individual variability in drug response can produce unexpected glucose shifts.

For patients starting finasteride while on Tresiba, a reasonable monitoring protocol includes:

• Baseline HbA1c and fasting glucose before starting finasteride
• Daily fasting glucose checks for the first 2 weeks, then 3 times weekly for weeks 3 through 8
• Follow-up HbA1c at 3 months to confirm no drift
• Symptom awareness for hypoglycemia (dizziness, sweating, confusion) or hyperglycemia (polyuria, polydipsia, fatigue)

Continuous glucose monitoring (CGM) users on Tresiba have an advantage here. The SWITCH 1 and SWITCH 2 trials, which compared insulin degludec to insulin glargine U100 in type 1 and type 2 diabetes respectively, showed that degludec produced 36% fewer nocturnal confirmed hypoglycemic episodes in the type 2 diabetes population (rate ratio 0.64 to 95% CI 0.42 to 0.98, P = 0.038) [10]. Patients on CGM can simply watch for trend changes in time-in-range after adding finasteride, which provides more granular data than intermittent fingerstick checks.

Finasteride Side Effects That Mimic or Mask Diabetes Symptoms

One practical clinical consideration that published interaction databases miss: certain finasteride side effects overlap symptomatically with diabetes-related concerns. Fatigue, reported by 2 to 5% of finasteride users in post-marketing surveillance [4], could be misattributed to hyperglycemia or hypoglycemia in a patient with diabetes. Similarly, mood changes and cognitive complaints reported by some finasteride users could obscure recognition of neuroglycopenic hypoglycemia symptoms.

The FDA added a warning to the finasteride label in 2012 noting reports of "depression" and "decreased libido that continued after discontinuation of the drug" [4]. For patients on insulin who rely on symptom recognition to detect hypoglycemia, any medication that alters mood or energy perception deserves flagging. This is not a drug interaction in the traditional pharmacological sense. It is a clinical management consideration that affects how reliably a patient can self-monitor.

Sexual dysfunction, reported in 3.4 to 15.8% of finasteride users depending on dose and study methodology [11], also intersects with diabetes care. Erectile dysfunction affects approximately 50% of men with diabetes [12], and disentangling finasteride-attributable sexual dysfunction from diabetes-attributable sexual dysfunction requires clear documentation of baseline function before starting finasteride.

Special Populations: Type 1 Diabetes and BPH Dosing

Patients with type 1 diabetes who use Tresiba and require finasteride represent a smaller but distinct population. Type 1 diabetes carries a different metabolic profile: these patients have absolute insulin deficiency rather than insulin resistance, and their glycemic control tends to be more brittle. The BEGIN Basal-Bolus Type 1 trial demonstrated that degludec achieved non-inferior HbA1c reduction versus insulin glargine U100 (estimated treatment difference -0.09%, 95% CI -0.23 to 0.05) with 25% lower rates of nocturnal hypoglycemia [13]. The stability of degludec's pharmacokinetic profile, with its coefficient of variation four times lower than glargine U100, provides a buffer against minor metabolic perturbations that might accompany finasteride initiation [5].

For BPH patients taking finasteride 5 mg (versus the 1 mg alopecia dose), the higher dose produces greater DHT suppression (approximately 90% versus 70% at the 1 mg dose) and a proportionally larger testosterone increase [4]. Whether this larger hormonal shift produces a detectable glycemic effect in insulin-treated patients has not been studied directly. The CPRD cohort study referenced above [7] included both 1 mg and 5 mg users and found no dose-dependent diabetes risk signal, but patients on basal insulin represent a more metabolically sensitive subgroup than the general population. Extra glucose monitoring vigilance for patients starting finasteride 5 mg while on Tresiba is a reasonable precaution.

When to Contact Your Prescriber

Patients taking both medications should reach out to their prescriber if they observe fasting glucose values consistently 20 mg/dL or more above their pre-finasteride baseline, if time-in-range on CGM drops by more than 10 percentage points over 2 or more weeks, or if they experience new or worsening symptoms of hypoglycemia. These thresholds are not specific to the finasteride-Tresiba combination. They reflect general diabetes management principles from the ADA Standards of Care [9] applied to the medication-addition scenario.

Patients should also inform their dermatologist or urologist that they use insulin. Prescribers managing finasteride may not routinely review a patient's diabetes medication list, and proactive communication ensures that all members of the care team are aware of the full regimen.

The Tresiba prescribing information recommends that "glucose monitoring is recommended for all patients with diabetes" and specifies that "the dose of Tresiba must be individualized based on clinical response" [3]. No fixed dose adjustment for finasteride co-administration is needed because no interaction altering insulin pharmacokinetics or pharmacodynamics has been identified.